Divergent coverage, frequency and costs of organised and opportunistic Pap testing in Finland

International Journal of Cancer

Volumn 135, Issue 1, 2014, Pages 204-213

  Salo, Heini ^a   Nieminen, Pekka ^b   Kilpi, Terhi ^a   Auranen, Kari ^a   Leino, Tuija ^a   Vänskä, Simopekka ^a,c   Tiihonen, Petri ^a   Lehtinen, Matti ^c   Anttila, Ahti ^d  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d FINNISH CANCER REGISTRY   (Finland)

Author keywords

cervical cancer screening; costs; opportunistic screening; organised programme; Pap test; screening coverage

Indexed keywords

CERVICAL CANCER SCREENING; COSTS; OPPORTUNISTIC SCREENING; ORGANISED PROGRAMME; PAP TEST; SCREENING COVERAGE;

ADULT; AGED; COSTS AND COST ANALYSIS; FEMALE; FINLAND; HUMANS; MASS SCREENING; MIDDLE AGED; PAPANICOLAOU TEST; PREGNANCY; REGISTRIES; UTERINE CERVICAL NEOPLASMS;

EID: 84899442576     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28646     Document Type: Article

References (35)

1. Anttila A, Pukkala E, Soderman B, et al. Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963-1995: recent increase in cervical cancer incidence. Int J Cancer 1999; 83: 59-65.
2. Government of Finland: Decree 1339/2006 on screenings. Helsinki, 2006.
3. Mass screenings/Cervical cancer screening. Finnish Cancer Registry, 2012. 06.03.2012 (cited 18.06.2013). Available at: http://www.cancer.fi/ syoparekisteri/en/mass-screening-registry/statistics/cervical-cancer-screening/.
4. Anttila A, Ronco G, Clifford G, et al. Cervical cancer screening programmes and policies in 18 European countries. Br J Cancer 2004; 91: 935-41.
5. Monto K, Nieminen P,. Gynekologisten irtosolunäytteiden määrät ja raportointitavat Suomessa. Suomen Lääkä rilehti 2005; 60: 2093-7.
6. Anttila A, von Karsa L, Aasmaa A, et al. Cervical cancer screening policies and coverage in Europe. Eur J Cancer 2009; 45: 2649-58.
7. Virtanen A, Anttila A, Luostarinen T, et al. Self-sampling versus reminder letter: effects on cervical cancer screening attendance and coverage in Finland. Int J Cancer 2011; 128: 2681-7.
8. Virtanen A, Nieminen P, Luostarinen T, et al. Self-sample HPV tests as an intervention for nonattendees of cervical cancer screening in Finland: a randomized trial. Cancer Epidemiol Biomarkers Prev 2011; 20: 1960-9.
9. Current Care Working Group. Cytological changes in the cervix, vagina and vulva (online). Current Care Guideline. Working group set up by the Finnish Medical Society Duodecim and the Finnish Colposcopy Association. Helsinki: Finnish Medical Society Duodecim. 2010 14.6.2010 [cited 19.06.2013]. Available at: www.kaypahoito.fi.
10. International Agency for Research on Cancer. IARC/WHO handbooks of cancer prevention, vol. 10: Cervix cancer screening. Lyon: IARC Press, 2005. 302.
11. Sasieni P, Castanon A, Cuzick J,. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ 2009; 339: b2968.
12. Gustafsson L, Adami HO,. Natural history of cervical neoplasia: consistent results obtained by an identification technique. Br J Cancer 1989; 60: 132-41.
13. van Oortmarssen GJ, Habbema JD,. Duration of preclinical cervical cancer and reduction in incidence of invasive cancer following negative pap smears. Int J Epidemiol 1995; 24: 300-7.
14. Moscicki AB, Shiboski S, Hills NK, et al. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 2004; 364: 1678-83.
15. Hristova L, Hakama M,. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017. Acta Oncol 1997; 36 (Suppl 9): 1-60.
16. Kalseth J, Halsteinli V, Halvorsen T, et al. Costs of cancer in the Nordic countries. A comparative study of health care costs and public income loss compensation. payments related to cancer in the Nordic countries in 2007, Trondheim: SINTEF Technology and Society. Health Services Research, 2011.
17. Arbyn M, Anttila A, Jordan J, et al. European guidelines for quality assurance in cervical cancer screening. Second edition-summary document. Ann Oncol 2010; 21: 448-58.
18. Salo H, Leino T, Kilpi T, et al. The burden and costs of prevention and management of genital disease caused by HPV in women: a population-based registry study in Finland. Int J Cancer 2013; 133: 1459-69.
19. Hujanen T, Kapiainen S, Tuominen U, et al, eds. Terveydenhuollon yksikkökustannukset Suomessa vuonna 2006, Helsinki: National Research and Development Centre for Welfare and Health (STAKES), 2008.
20. Leinonen MK, Nieminen P, Lonnberg S, et al. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland. BMJ 2012; 345: e7789.
21. von Karsa L, Anttila A, Ronco G, et al. Cancer screening in the European Union. Report on the implementation of the council recommendation on cancer screening, first report. International Agency for Research on Cancer and Directorate General for Health and Consumers. European Communities, 2008.
22. Nygard JF, Skare GB, Thoresen SO,. The cervical cancer screening programme in Norway, 1992-2000: changes in Pap smear coverage and incidence of cervical cancer. J Med Screen 2002; 9: 86-91.
23. Rebolj M, van Ballegooijen M, Berkers LM, et al. Monitoring a national cancer prevention program: successful changes in cervical cancer screening in the Netherlands. Int J Cancer 2007; 120: 806-12.
24. Ronco G, van Ballegooijen M, Becker N, et al. Process performance of cervical screening programmes in Europe. Eur J Cancer 2009; 45: 2659-70.
25. de Kok IM, van der Aa MA, van Ballegooijen M, et al. Trends in cervical cancer in the Netherlands until 2007: has the bottom been reached? Int J Cancer 2011; 128: 2174-81.
26. Health expenditure and financing 2011. National Institute for Health and Welfare (THL), Helsinki, 2013.
27. Anttila A, Nieminen P,. Cervical cancer screening programme in Finland with an example on implementing alternative screening methods. Coll Antropol 2007; 31 (Suppl 2): 17-22.
28. Anttila A, Pukkala E, Soderman B, et al. Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963-1995: recent increase in cervical cancer incidence. Int J Cancer 1999; 83: 59-65.
29. Cervical cancer incidence in Finland. NORDCAN: cancer incidence, mortality, prevalence and survival in the Nordic countries Association of the Nordic Cancer Registries. 2012. Available at: http://www.ancr.nu.
30. Laukkanen P, Koskela P, Pukkala E, et al. Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J Gen Virol 2003; 84: 2105-9.
31. Lehtinen M, Kaasila M, Pasanen K, et al. Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s. Int J Cancer 2006; 119: 2612-9.
32. Tobacco statistics 2011, Helsinki: National Institute for Health and Welfare (THL), 2012.
33. Nieminen P, Kallio M, Anttila A, et al. Organised vs. spontaneous pap-smear screening for cervical cancer: a case-control study. Int J Cancer 1999; 83: 55-8.
34. Munoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010; 102: 325-39.
35. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13: 89-99.